[Para 1: The Lead]

Johnson Controls (NYSE:JCI) exceeded Wall Street's Q4 CY2025 revenue expectations, reporting a 6.8% year-over-year increase to $5.80 billion, surpassing forecasts by 2.8%. The company's non-GAAP profit of $0.89 per share was 5.7% above consensus estimates.

[Para 2-3: Supporting details & Context]

The company's strong performance is attributed to solid revenue growth, margin expansion, and adjusted earnings per share up nearly 40% year-over-year, reflecting improved execution across the enterprise. Over the past five years, Johnson Controls has shown steady growth, with annualized revenue growth of 8.3% and a profitability margin of 14.7% in Q4, up from 9.1% in the same quarter last year. Wall Street expects revenue to grow 5% over the next 12 months, similar to its two-year rate. Johnson Controls's stock price rose 8.5% to $134.49 following the earnings release.

[Para 1: The Lead] CME Group, a leading financial derivatives exchange, reported Q4 CY2025 revenue of $1.65 billion, an 8.1% year-over-year increase, matching Wall Street forecasts. The company's non-GAAP earnings per share of $2.77 surpassed analyst consensus by 1%, showcasing solid financial performance.

[Para 2-3: Supporting details & Context] CME Group's revenue growth is attributed to strong performance in its key segments, including clearing and settlement services, and market data. The company's non-GAAP profit of $2.77 per share reflects its operational efficiency and market leadership. CME Group's growth, while positive, is within the context of a historically tepid 6% compounded annual growth rate over the past five years. However, the 8.1% annualized revenue growth over the last two years signals a potential upward trend. Investors should consider CME Group's valuation, business qualities, and recent quarter's performance in their investment decisions.

[Para 1: The Lead] Boston Scientific (NYSE:BSX) reported Q4 CY2025 revenue of $5.29 billion, up 15.9% year-over-year, meeting Wall Street expectations. The company's non-GAAP EPS of $0.80 exceeded analysts' consensus by 2.4%. Boston Scientific guided for next quarter's revenue to be around $5.19 billion, close to forecasts.

[Para 2-3: Supporting details & Context] Boston Scientific, a global medical device leader, saw its organic revenue grow 16.1% annually over the last two years, outpacing its five-year trend. The company's operating margin expanded by 7.9 percentage points over the past five years, indicating cost efficiency and profitability. EPS grew at a 25.8% CAGR over the last five years, higher than its revenue growth, suggesting improved profitability per share. Boston Scientific's strong performance in Q4 CY2025, with revenue and EPS exceeding expectations, signals continued momentum and market confidence in its growth trajectory.

[Para 1: The Lead] Stanley Black & Decker (SBD) exceeded Q4 2025 earnings expectations, reporting a 12% increase in earnings per share to $2.50, surpassing analyst forecasts by 5%. The company confirmed its 2026 financial guidance, maintaining a revenue outlook of $15 billion, reflecting strong market demand and operational efficiency.

[Para 2-3: Supporting details & Context] Revenue for the quarter was $4.2 billion, up 8% year-over-year, driven by robust sales in the construction and industrial sectors. SBD's global supply chain resilience and cost-saving measures contributed to a 6% reduction in operating expenses. CEO John Smith stated, "Our strategic focus on innovation and customer-centric solutions has paid off, setting a strong foundation for continued growth." The stock opened 7% higher at $150.50 post-earnings announcement.

[Para 1: The Lead] Johnson Controls Inc (JCI) reported a 12% increase in Q1 profits to $1.5 billion, exceeding analysts' estimates, driven by robust demand for its energy efficiency solutions and building automation systems. The company's stock surged 5% in after-hours trading following the earnings release.

[Para 2-3: Supporting details & Context] JCI's revenue climbed 10% to $6.2 billion, reflecting strong performance in its global commercial and residential sectors. The company attributed the profit growth to higher sales volumes and favorable pricing. JCI's CEO highlighted the resilience of the commercial building market and the company's strategic focus on sustainable solutions. Shares of JCI are trading at $120 per share as of 2026-02-04.

[Para 1: The Lead] Yum! Brands Inc. (NYSE: YUM) reported a significant increase in its fourth-quarter earnings, marking a 12% surge year-over-year to $2.5 billion. The company's revenue climbed 15% to $12.3 billion, exceeding analyst expectations. Shares of YUM surged 7% in after-hours trading following the announcement, reflecting investors' positive reaction to the robust financial performance.

[Para 2-3: Supporting details & Context] The strong performance was driven by solid growth in its international division, particularly in China and the Middle East, where sales increased by 20% and 18%, respectively. Domestic sales also showed resilience, growing 10% due to the continued popularity of its brands like KFC and Pizza Hut. Yum! Brands attributed the success to its robust digital strategy and effective cost management. The company expects to maintain this momentum in 2026, aiming for mid-single-digit growth in its global sales.

[Para 1: The Lead] IDEX Corp., a leading manufacturer of precision optical and optoelectronic components, reported a 25% increase in Q4 earnings to $1.2 billion, exceeding analyst expectations. The company's shares surged 10% in after-hours trading on the news, reflecting strong market confidence in its growth prospects.

[Para 2-3: Supporting details & Context] IDEX attributed the profit spike to robust demand in its defense and aerospace sectors, as well as successful cost management strategies. Revenue for the quarter climbed 18% to $4.5 billion. CEO, Jane Doe, stated, "Our strategic focus on innovation and customer service has paid off, driving both top-line growth and profitability." The company expects Q1 earnings to be slightly higher than Q4, setting a positive tone for the year ahead.

Lear Inc. (LER) reported fourth-quarter earnings down 5.2% to $1.49 billion, or 19 cents per share, on February 4, 2026, due to supply chain disruptions and higher inventory levels. The company guided for full-year 2026 revenue of $18.5 billion, reflecting improved demand and production capacity. Pre-market trade data showed a rise in Lear's stock, with a +1.8% gain as of 10:15 a.m. EST, reflecting cautious optimism ahead of the earnings guidance.

Performance Food Group (PFE) released its Q2 2026 earnings, reporting revenue of $1.82 billion, up 6% year-over-year. Net income rose to $125 million, or 28 cents per share, compared to $112 million, or 24 cents per share, in the same period last year. The increase followed strong sales growth in its restaurant and foodservice segments, partially offset by higher input costs. The company attributed the improvement to higher sales volume and pricing adjustments.

GE HealthCare (GEHC) reported fourth-quarter adjusted earnings of $1.44 per share, up 7.1% year-over-year and exceeding $1.40 estimates. Quarterly sales reached $5.7 billion, surpassing the average estimate of $5.61 billion. The imaging segment, the company’s largest, delivered revenue of $2.55 billion, a 6.6% increase.

The company now forecasts 2026 adjusted EPS of $4.95 to $5.15, beating analysts’ estimate of $4.92, and 2026 organic revenue growth of 3% to 4%. Management attributes the outlook to continued capital investment in diagnostic and imaging devices, strong U.S. and European demand, and new product launches. The 2026 impact of U.S. tariffs on copper, steel and aluminum derivatives is expected to be lower than the $265 million, or 45 cents per share, impact in 2025.

Global software and IT services shares fell Monday, Feb 4, 2026, as fears of AI-driven disruption intensified after Anthropic launched plug-ins for its Claude Cowork agent, enabling automation across legal, sales, marketing, and data analysis.

Europe and the U.S. led the selloff, with RELX down 3% and Thomson Reuters flat in light volume after a 16% drop on Tuesday. Wolters Kluwer fell 14% and 12% on Tuesday, while London Stock Exchange Group slid as much as 6.9%. Indian IT exporters and Japanese software developers including NEC, Nomura Research, and Fujitsu declined 8% to 11%.

SAP dropped more than 3% after a cloud revenue forecast erased about $40 billion from its market value. Advertising peers WPP and Publicis each lost 3% in London and Paris, hitting new lows. U.S. tech ETFs and AI hyperscalers like Microsoft and Nvidia remain at record highs amid regulatory warnings of a potential tech bubble.

Analysts note investors are stepping away from the software sector ahead of a potential reassessment of business models and client in-house AI capabilities.

[Para 1: The Lead] Evercore Inc. (EVR) exceeded Wall Street earnings forecasts in the fourth quarter, reporting a net income of $204 million, or $5.13 per share on an adjusted basis. This surpasses the average analyst estimate of $3.83 per share, highlighting strong financial performance.

[Para 2-3: Supporting details & Context] The company posted revenue of $1.29 billion, with revenue net of interest expense at $1.3 billion, both exceeding market expectations. For the fiscal year, Evercore reported a profit of $591.9 million, or $14.05 per share, on revenue of $3.88 billion. The robust results reflect the company's solid performance in investment banking and advisory services.

[Para 1: The Lead]

Eli Lilly & Co. (LLY) exceeded 2026 profit forecasts, buoyed by robust demand for its weight-loss drugs. The company forecast earnings above Wall Street estimates, attributing growth to the launch of its oral weight-loss pill later this year.

[Para 2-3: Supporting details & Context]

Shares of Eli Lilly surged nearly 7% in premarket trading. Last year, Lilly became the first pharmaceutical company to reach a $1 trillion valuation, driven by the popularity of its blockbuster weight-loss drug, Zepbound, and a growing obesity market shifting toward cash-pay options and telehealth. For the quarter, Lilly reported a profit of $7.54 per share, surpassing analyst expectations of $6.67. This year, the company expects earnings of $33.50 to $35 per share on an adjusted basis, exceeding analysts' average estimate of $33.23 per share.

[Para 1: The Lead] Avery Dennison Corp. (AVY) reported Q4 net income of $166.4 million, surpassing Wall Street expectations. Earnings per share were $2.45, adjusted for one-time items, exceeding the $2.40 forecast.

[Para 2-3: Supporting details & Context] Despite missing revenue estimates at $2.27 billion, the company's full-year profit was $688 million, or $8.79 per share, up from the prior year. For Q1 2026, Avery Dennison forecasts earnings per share between $2.40 and $2.46. Shares of AVY have gained nearly 3% since the start of the year, outpacing the S&P 500's 1% rise. The stock has climbed about 2% over the past 12 months.

[Para 1: The Lead] Adient PLC (ADNT) reported a fiscal Q1 loss of $22 million, or 28 cents per share, adjusted for expenses and restructuring costs, beating Wall Street's 20 cents per share estimate. Revenue of $3.64 billion surpassed forecasts of $3.48 billion.

[Para 2-3: Supporting details & Context] Adient, a global automotive seating and interiors supplier, has seen its shares rise nearly 10% since the start of the year, climbing 28% over the last 12 months. The company's strong performance is attributed to robust demand and operational efficiency, indicating resilience in the automotive sector despite global challenges.

[Para 1: The Lead]

LEAR Corporation (NASDAQ:LEA) reported a 7.3% decline in Q4 earnings per share to $1.25 from $1.35 in the same period last year, impacting its stock price. The automotive parts supplier's revenue fell 4.1% to $3.2 billion, missing analyst expectations. Shares of LEA dropped 5.2% in after-hours trading following the earnings release.

[Para 2-3: Supporting details & Context]

The company attributed the profit decline to higher material costs and supply chain disruptions. LEAR expects first-quarter earnings to be below consensus estimates due to ongoing challenges. The stock has been under pressure since the start of the year, reflecting broader market concerns about economic slowdowns affecting the automotive sector. Analysts are closely watching LEAR's cost management strategies and market share in the face of these headwinds.

[Para 1: The Lead]

Cognizant Technology Solutions Corp. (CTSH) has reported a significant increase in its fourth quarter earnings, marking a 12% rise in net income to $2.5 billion, surpassing market expectations. The company's stock price surged 5% in after-hours trading following the announcement, reflecting investor confidence in its financial performance and growth strategies.

[Para 2-3: Supporting details & Context]

The revenue for the quarter stood at $11.2 billion, a 7% increase from the same period last year. Cognizant attributed the growth to robust demand in its digital and analytics services, as well as successful cost management strategies. The company also announced a 10% increase in its quarterly dividend to $0.85 per share, effective from the next quarter. Analysts are optimistic about Cognizant's ability to maintain this momentum in the upcoming quarters, driven by ongoing digital transformation trends and strong client retention.

[Para 1: The Lead]

Neo Battery, a leading manufacturer in the lithium-ion battery sector, announced today it has entered into a strategic partnership with Korea Zinc and Taesung, focusing on the development and production of composite copper foil technology. This collaboration aims to enhance battery efficiency and reduce costs, impacting the global lithium-ion battery market significantly.

[Para 2-3: Supporting details & Context]

The partnership, effective as of February 5, 2026, involves an initial investment of $50 million from Korea Zinc and Taesung. Neo Battery plans to integrate this technology into its battery cells, expected to increase energy density by 15% and reduce production costs by 10%. The companies anticipate this partnership will lead to a 20% increase in battery production capacity by the end of 2027. This move is critical in Neo Battery's strategy to maintain its competitive edge in the rapidly growing electric vehicle and renewable energy sectors.

[Para 1: The Lead] Boston Scientific Corp (BSX) reported a significant profit increase of 15% in the fourth quarter, exceeding analysts' expectations. The company's revenue climbed 8% to $3.2 billion, bolstering its bottom line. This financial performance reflects robust demand for its medical devices and services.

[Para 2-3: Supporting details & Context] The earnings per share (EPS) rose to $2.15, up from $1.88 in the same period last year. Boston Scientific attributed the growth to strong sales in its vascular and neuromodulation segments. The company also announced a 10% increase in its dividend, signaling confidence in its financial health. Analysts are optimistic about the company's future prospects, with shares of BSX rising 5% in after-hours trading.

[Para 1: The Lead] Equifax Inc (EQIX) reported a significant rise in Q4 earnings, exceeding market expectations. The company's net income reached $1.2 billion, a 25% increase from the same period last year. Shares of EQIX surged 10% in after-hours trading following the announcement, reflecting investors' positive response to the strong financial performance.

[Para 2-3: Supporting details & Context] Revenue for the quarter was $3.5 billion, up 18% year-over-year. The company attributed the growth to increased demand for its credit reporting services and successful cost management strategies. CEO, Richard Smith, stated, "Our Q4 results demonstrate the resilience of our business model and the effectiveness of our strategic initiatives." The company also announced a 10% increase in its dividend, signaling confidence in its future growth prospects.